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Objectives. We tested whether a new class III drug (MS-551)
administered during ventricular fibrillation (VF) could decrease
the defibrillation threshold (DFT) in anesthetized canine hearts.
Background. Pretreatment with class III antiarrhythmic agents
is known to enhance electrical defibrillation efficacy.
Methods. In a preliminary study (n 5 10), we ascertained the
validity of DFT determination by a sequence of incremental
defibrillation shocks in a single fibrillation/defibrillation episode.
We then compared the DFTs after 130 s of VF with and without
administration of MS-551 (2 mg/kg body weight) at 10 s after the
onset of VF in 12 open chest dogs and 8 closed chest dogs.
Results. MS-551 decreased the DFT in both experimental
models (open chest [mean 6SD]: from 416 6 106 to 318 6 92 V,
p < 0.05; closed chest: from 714 6 75 to 615 6 112 V, p < 0.05).
The change (D) in DFT in each heart was inversely correlated with
the drug-induced prolongation of VF cycle length before the
defibrillation attempt (DDFT vs. DVF cycle length 10 s before the
first discharge: r 5 20.58 and 20.81, p < 0.05).
Conclusions. MS-551 given after the induction of VF improved
defibrillation efficacy. Class III antiarrhythmic agents deserve
consideration when VF is resistant to electrical defibrillation
during cardiopulmonary resuscitation.
(J Am Coll Cardiol 1997;29:688–92)
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The recent advent of the automatic implantable cardioverter-
defibrillator has raised interest in how antiarrhythmic agents
influence electrical defibrillation efficacy (1). In general, so-
dium channel blockade decreases the defibrillation efficacy,
whereas prolongation of the action potential duration in-
creases it (2–12). Specifically, long-term treatment with class
III drugs, such as sotalol, is believed to facilitate defibrillation
in patients with implanted cardioverter-defibrillators (12).
However, it remains unknown whether these drugs can exert a
favorable effect when administered during an episode of
ventricular fibrillation (VF). In an attempt to extend the role of
class III drugs in critical care medicine, we tested the effect on
the defibrillation threshold (DFT) of a new nonspecific K1
channel blocker, MS-551 (13,14), when given after the induc-
tion of VF.
Methods
This study was carried out in four stages. The conventional
DFT (conDFT) is determined by repeated fibrillation/
defibrillation episodes that generally contain only one test
shock plus one or more rescue shocks, if necessary (15).
However, the effect of an acute intervention during VF needs
to be estimated within a single episode. Therefore, we used a
DFT defined by a sequence of incremental test shocks
(seqDFT) in our main studies (studies 3 and 4). Study 1 was a
preliminary study designed to validate this DFT by comparison
with the conDFT and by inspecting its reproducibility. As an
indication of the electrophysiologic action of MS-551, we
analyzed the temporal profile of the VF cycle length (VF-CL)
in studies 3 and 4. To confirm that the VF-CL reliably reflected
drug-induced modulation of the action potential duration, we
compared the changes of the monophasic action potential
duration and VF-CL caused by MS-551 in study 2. Finally,
effects of MS-551 given after the induction of VF on DFT were
tested in open (study 3) and closed chest dogs (study 4).
Animal preparation. Thirty mongrel dogs weighing 7 to
15 kg were anesthetized with a bolus of intravenous sodium
pentobarbital (30 mg/kg body weight), followed by continuous
infusion at 1 to 5 mg/kg per h (16). Dogs were intubated with
a cuffed endotracheal tube and ventilated with a mixture of
room air and 100% oxygen through a Harvard respirator. Body
temperature was maintained at about 378C with an electric
blanket. Arterial blood pressure was monitored using a left
femoral artery cannula attached to a Statham pressure trans-
ducer (Amplifier AP621G, Nihon Kohden, Tokyo, Japan).
Arterial blood gases and electrolytes were periodically deter-
mined by a portable clinical analyzer (i-STAT 200A, i-STAT
Corporation), and abnormal pH, partial pressures of oxygen
and carbon dioxide and K1 values were corrected appropri-
ately.
In 22 dogs used for studies 1 to 3, the heart was exposed by
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a midsternal incision, and a pair of square titanium defibrilla-
tion electrodes with a 4-cm2 surface area were sutured to the
pericardium over the right and left ventricles. In the remaining
eight dogs for study 4, a pair of external defibrillation pads
(79 cm2 and 112.5 cm2: PD-2200, Zoll Medical Corporation)
was applied on the anterior and posterior thoracic walls after
skin treatment. Defibrillation shocks were provided by a
programmable two-capacitor (165 mF 3 2) discharge unit that
could delivery truncated exponential pulses at preset voltages
up to 800 V (DPS-1200D, Diamedical, Tokyo, Japan). When
calibrated with a 200-ohm load at 500 V, a 6-ms monophasic
shock had a 16% tilt. To ensure appropriate shock delivery, the
current waveform was monitored on a digitized oscilloscope
(model 5020A, Kikusui, Tokyo, Japan). Two bipolar epicardial
electrograms (studies 1 to 3: 50 to 1 kHz) or one bipolar
endocardial electrogram (study 4) as well as two surface
electrocardiograms were continuously monitored, and they
were recorded on an ink-jet recorder (RIJ-2108, Nihon
Kohden) together with the arterial blood pressure at a paper
speed of 25 or 50 mm/s.
Study 1 (n 5 10). Ventricular fibrillation was induced by a
2-s train of 4-ms pulses (100 Hz) through a unipolar electrode
on the right ventricle. After 10 s of VF, a 6-ms monophasic
sock at a strength of 300 V was applied first. Then an iterative
increment-decrement protocol was used, with the steps being
;10% of the preset voltage. We defined the conDFT as the
voltage of the successful shock, when the next lower setting
failed to defibrillate the heart in the preceding or subsequent
attempt. Only the result of the first test shock of each
defibrillation attempt was used in determination of the DFT.
Fibrillation/defibrillation episodes were separated by at least
4 min and were repeated until triplicate DFT values were
determined. The mean of the triplicate values was then taken
to represent the conDFT after 10 s of VF (conDFT 2 10 s).
To determine the seqDFT after 10 s of VF (seqDFT 2
10 s), 6-ms shocks were consecutively delivered at intervals of
4 to 6 s. The first shock was set at 60% of conDFT 2 10 s, and
the voltage of subsequent shocks was increased stepwise by
20% of conDFT 2 10 s (i.e., 80%, 100%, 120%, 140%, 160%,
180% of conDFT 2 10 s). The seqDFT 2 10 s was defined by
the voltage of the successful shock. The seqDFT 2 70 s and
seqDFT 2 130 s were determined in a similar way. However,
to simulate clinical resuscitation and to alleviate hemodynamic
deterioration due to prolonged VF, manual direct cardiac
massage was started after 10 s of VF and was continued until
the first discharge. The rate of cardiac compression was 2/s or
slightly lower, and the femoral systolic blood pressure was
maintained at ;50 mm Hg. The values of seqDFT 2 10 s,
seqDFT 2 70 s and seqDFT 2 130 s were determined twice in
succession. Fibrillation/defibrillation episodes were separated
by at least 15 min, and the order of measurement of seqDFT
was not randomized.
Study 2 (n 5 5). After completion of study 1, 5 of the 10
dogs were subjected to this study. The monophasic action
potential was recorded from the anterior surface of the right
ventricle via a suction electrode (interelectrode distance 3 mm)
during right ventricular pacing at a cycle length of 350 ms.
Monophasic action potential signals were amplified and fil-
tered at a frequency of 0.05 and 1 kHz. The duration of
monophasic action potential was determined at 90% repolar-
ization (MAP90), after which VF was electrically induced. The
VF-CL corresponding to the preceding MAP90 was calculated
by averaging 4 to 10 VF-CL values from either the right or left
ventricular bipolar electrogram after about 10 s of VF. After
baseline measurement of the paired MAP90 and VF-CL,
0.1 mg/kg of MS-551 was intravenously administered as a
bolus. MS-551 has been reported to block the delayed rectifier
(Ik), the inward rectifier (Ik1) and the transient outward (Ito)
K1 channels (12). Fifteen minutes later, both variables were
measured in the same manner as at baseline. Subsequently,
MS-551 was cumulatively given at doses of 0.2, 0.4 and
0.8 mg/kg, with measurement of MAP90 and VF-CL being
repeated at each dose.
Study 3 (n5 12). Twelve dogs were subjected solely to this
study. As a control, seqDFT 2 130 s was obtained without
MS-551 using the same method as in study 1. After at least
20 min, seqDFT 2 130 s was reassessed after MS-551
(2 mg/kg) administration as a bolus through the femoral vein at
10 s after the onset of VF (Fig. 1). Blood samples for
Abbreviations and Acronyms






5 conDFT determined at 10-s VF and
seqDFTs determined by sequential
shocks applied at 10, 70 or 130 s of VF,
respectively
DFT 5 defibrillation threshold
MAP90 5 duration of monophasic action potential
determined at 90% repolarization
seqDFT 5 defibrillation threshold determined by
sequence of incremental shocks
VF 5 ventricular fibrillation
VF-CL 5 cycle length ventricular fibrillation
Figure 1. Diagram of experimental protocol. Ten seconds after VF
was induced by 100-Hz train pulses, MS-551 was administered through
the femoral vein. Simultaneously, cardiac massage was started and
continued until the first defibrillation discharge. Arterial blood sam-
ples were obtained 30, 60 and 120 s after drug infusion. Incremental
shocks were delivered consecutively until defibrillation occurred, so
the number of shocks was not constant.
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determination of the plasma drug concentration at 30, 60 and
120 s after MS-551 infusion were acquired through a long
catheter introduced into the aortic arch. The local VF-CL was
calculated every 10 s during fibrillation/defibrillation episodes
with and without MS-551 using the same method as in study 2.
Study 4 (n 5 8). Eight closed chest dogs were subjected
solely to this study. Because maximal voltage of our defibril-
lation unit was limited, smaller dogs (7 to 10 kg) were used. All
the experimental procedures were as in study 3, except that VF
was induced through the catheter electrode in the right
ventricle, and transthoracic defibrillation shocks were applied
to the heart.
Data analysis and statistical methods. Results are ex-
pressed as mean value 6 SD. The significance of differences
between paired values was tested by Student t test. Comparison
among three or more values was done by two-way analysis of
variance. In the presence of a significant F value, further
comparisons between each pair of variables were done by the
Bonferroni method. Correlations between two variables were
tested by linear regression analysis. Probability values ,0.05
were considered to indicate significance.
Results
Study 1. The conDFT 2 10 s was 285 6 107 V. The
seqDFT 2 10 s was 272 6 109 V (p 5 NS vs. conDFT 2 10 s)
(Fig. 2), and there was a significant correlation between these
two thresholds (r 5 0.96, p , 0.001). The second measured
value of each seqDFT was not significantly different from the
initial measurement (seqDFT 2 10 s: 4 6 18%, seqDFT 2
70 s: 3 6 25%; seqDFT 2 130 s: 16 6 19%), and their
correlation was always strong (r 5 0.92, p , 0.001; r 5 0.86,
p , 0.005; r 5 0.94, p , 0.001). The seqDFT 2 130 s was
higher than seqDFT 2 10 s (p , 0.05) (Fig. 2).
Study 2. The baseline MAP90 was 209 6 21 ms. It was
uniformly prolonged as the cumulative dose of MS-551 in-
creased (223 6 25, 234 6 30, 251 6 33 and 256 6 35 ms, p ,
0.001). There was a dose-dependent increase in VF-CL from
the baseline value of 124 6 23 ms (148 6 31, 166 6 32, 176 6
37 and 187 6 43 ms, p , 0.001). Consequently, the linear
relation between VF-CL and MAP90 was significant in all five
dogs, as shown in Figure 3. The individual correlation coeffi-
cients ranged from 0.92 (p , 0.05) to 0.99 (p , 0.005).
Study 3. The seqDFT 2 130 s without MS-551 was 416 6
106 V, and administration of MS-551 decreased this value in 8
of 12 dogs. Overall, the seqDFT 2 130 s after MS-551
administration (318 6 92 V) was significantly lower than
before the drug was given (p , 0.05) (Fig. 4A).
In the absence of MS-551, the VF-CL was largely constant
throughout VF (Fig. 5A). In contrast, MS-551 caused a
time-dependent prolongation of VF-CL. The difference in the
VF-CL values in the presence and absence of MS-551 became
significant at 40 s after drug infusion. The drug-induced change
in VF-CL at 120 s of VF (i.e., 10 s before first discharge) was
inversely correlated with the changes in seqDFT 2 130 s (r 5
20.58, p , 0.05).
The plasma MS-551 concentration at 30, 60 and 120 s after
drug infusion was 25 6 27, 43 6 34 and 24 6 12 mg/ml,
respectively. MS-551-induced changes of seqDFT 2 130 s did
not show any definite relation to the plasma drug level at any
of these three times.
Study 4. The seqDFT 2 130 s after MS-551 administration
(615 6 112 V) was lower than the baseline value (714 6 75 V,
p , 0.05) (Fig. 4B). The difference in the VF-CL values in the
Figure 2. Comparison of conDFT (solid bar) and seqDFT (hatched
bars). At 10 s of VF, seqDFT was comparable to conDFT.
Figure 3. VF-CL after 10 s of VF in relation to MAP90 during
ventricular pacing at a cycle length of 350 ms. Different symbols
indicate different animals. Each line was drawn in the order of
measurement, with the left and right ends corresponding to baseline
and 0.8 mg/kg of MS-551, respectively. The linear relation between
both variables is distinct.
Figure 4. A, Comparison of seqDFT values obtained in the absence
and presence of MS-551 infusion in study 3 (open chest dogs). Barred
circles 5 mean values. B, Comparison of seqDFT values in study 4
(closed chest dogs).
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presence and absence of MS-551 became significant at 70 s
after drug infusion. The drug-induced change in VF-CL at
120 s of VF was inversely correlated with the changes in
seqDFT 2 130 s (r 5 20.81, p , 0.05).
The plasma MS-551 concentration at 30, 60 and 120 s after
drug infusion was 41 6 29, 21 6 8 and 17 6 8 mg/ml,
respectively. MS-551-induced changes in seqDFT 2 130 s did
not show any significant relation to the plasma drug level.
Discussion
The chief findings of the present study were as follows: 1)
the DFT obtained with sequential multiple shocks showed
excellent reproducibility and time-dependent increases; 2)
defibrillation efficacy was significantly improved when MS-551
was given after the induction of VF in both open and closed
chest dogs.
Effect of antiarrhythmic agents on DFT. With the excep-
tion of a few reports (17,18), most studies have shown that
antiarrhythmic agents with a class Ib or Ic action reduce
defibrilllation efficacy in both animal and human hearts (2–9).
Most drugs with a class III action (2,11,12), but probably not
amiodarone (19,20), decrease the DFT. Accordingly, drugs
with class Ia action have a small, if any, effect on the DFT,
probably because their adverse and favorable effects cancel
each other (2,9,10).
However, earlier experimental and clinical studies have
focused on how pretreatment with antiarrhythmic drugs influ-
enced defibrillation efficacy. To our knowledge, no systematic
investigation has been performed concerning the effect of
antiarrhythmic agents given during VF. To show prompt
electrophysiologic action, drugs need to reach the myocardium
and block certain ion channels without delay. In addition, the
reverse-frequency dependence that is characteristic of some
class III drugs (21) diminishes their pharmacologic effect.
Thus, it has been unclear whether class III drugs given during
VF with its hemodynamic deterioration can favorably affect the
defibrillation efficacy. However, the present study indicated
that the defibrillation efficacy was enhanced when MS-551 was
given after the onset of VF. This observation suggests the
possible usefulness of class III antiarrhythmic drugs in patients
who are refractory to electrical defibrillation.
DFT measurement with sequential shocks. We quantified
the defibrillation efficacy using multiple incremental shocks.
This procedure has the advantage that only a single fibrillation/
defibrillation sequence can determine the DFT. However, its
demerits are as follows: 1) Very few earlier data are available
for comparison (22). 2) The time required for multiple shocks
and the sequelae of subthreshold shocks are not taken into
consideration. Time-dependent increase of DFT should be
important to estimate the actual merit of pharmacologic
modification of defibrillation efficacy. 3) The precision of the
measurements is affected by the arrangement of shock
strengths. Despite these potential problems, study 1 showed
that seqDFT 2 10 s was similar to conDFT 2 10 s, and the
small variability of seqDFT values between measurements was
supportive of their excellent reproducibility. On the basis of
these observations, we considered that seqDFT was an appro-
priate variable for the purposes of the present study.
Time course of electrophysiologic manifestations of
MS-551. Although the interval of local activation during VF
varies from beat to beat, some studies have utilized VF-CL as
an indicator of the refractoriness of regional myocardial tissue
(23,24). Our study 2 revealed a distinct association between
MAP90 and VF-CL. Although a quantitative relation of
MAP90 and VF-CL may not be common, these results con-
firmed that VF-CL is a sensitive indicator of regional myocar-
dial refractoriness.
VF-CL began to increase ;40 s after injection of MS-551
(Fig. 5). This time-dependent prolongation of VF-CL presum-
ably represented arrival of the drug in the heart and its
pharmacologic action. Although the transport and diffusion of
a drug are dependent on several factors, such as cardiac output
and site of infusion, the electrophysiologic action of MS-551
seemed to be detectable soon after the drug reached the heart.
In contrast, we failed to demonstrate a clear relation between
the plasma drug level and changes in defibrillation efficacy.
This may be explained by the fact that the plasma level did not
necessarily correspond to the tissue level of MS-551 because of
variable circulation during cardiopulmonary resuscitation or
because its modulation of K1 channels differed in individual
hearts.
Figure 5. A, Comparison of time course of VF-CL with and without
MS-551 in 12 open chest dogs (study 3). VF-CL is almost constant in
the baseline state. When MS-551 was given at 10 s of VF, there was
appreciable prolongation of VF-CL at ;40 s after infusion. This
drug-induced prolongation of VF-CL was time dependent. B, Time
course of VF-CL in eight closed chest dogs (study 4). *p , 0.005,
**p , 0.001 versus baseline.
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In the clinical setting, physicians prefer early defibrillation.
Because we only assessed the influence of MS-551 at 120 s
after injection, information about when the drug begins to
improve defibrillation efficacy is lacking. On the basis of the
inverse relation between the prolongation of VF-CL and
changes in seqDFT 2 130 s, MS-551 may well have influenced
defibrillation efficacy from 40 to 60 s after infusion. However,
the magnitude of its immediate effect (,1 min after infusion)
would probably be too small to detect and may have limited
clinical significance.
Study limitations. Extrapolation of the results obtained in
intact hearts to diseased hearts is limited. Also, it is not clear
whether external cardiac massage in the clinical setting can
effectively transport the drug from peripheral vessels to the
heart, as it did in our experimental models (25,26). Further-
more, we gave MS-551 only 10 s after the onset of VF, whereas
several unsuccessful defibrillation attempts are usually made
before initiation of interventions to facilitate defibrillation in
the clinical setting. Therefore, metabolic abnormalities caused
by prolonged VF before treatment with a class III drug might
attenuate its effect.
Conclusions. When MS-551 was infused during VF, it
successfully enhanced defibrillation efficacy in canine hearts.
This finding suggests that class III antiarrhythmic agents
deserve consideration when VF is resistant to electrical defi-
brillation or when an unacceptably high DFT is anticipated.
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